SHENZHOU INTL(02313) announces annual performance, with a net profit after tax of approximately 5.825 billion yuan, a year-on-year decrease of about 6.7%.
Belle International Holdings Limited (02313) released its annual performance for the year ending December 31, 2025. The group achieved a revenue of 30.994 billion yuan, an increase of 8.13% year-on-year. The equity attributable to owners of the parent company was 5.825 billion yuan, a decrease of 6.66% year-on-year. Earnings per share were 3.88 yuan, with a proposed final dividend of 1.2 Hong Kong dollars per share.
SHENZHOU INTL(02313) announced its annual performance for the year ending December 31, 2025. The group achieved a revenue of RMB 30.994 billion, an increase of 8.13% year-on-year. The equity attributable to owners of the parent company was RMB 5.825 billion, a decrease of 6.66% year-on-year. Earnings per share were RMB 3.88, with a proposed final dividend of HK$1.2 per share.
For the year ending December 31, 2025, the sales of sports products accounted for approximately 67.7% of total sales. The sales of sports products increased by about 5.9% compared to the 2024 fiscal year, mainly due to increased demand for sports products in the American and European markets.
For the year ending December 31, 2025, the sales of leisure products accounted for about 27.1% of total sales. The sales of leisure products increased significantly by about 16.7% compared to the 2024 fiscal year, mainly due to a significant increase in demand for leisure products in Japan and other markets.
For the year ending December 31, 2025, the sales of underwear products accounted for about 4.5% of total sales. The sales of underwear products slightly decreased by about 2.3% compared to the 2024 fiscal year, mainly due to a decline in demand for underwear products in the Japanese market.
The net profit after tax for the year ending December 31, 2025 was approximately RMB 5.825 billion, a decrease of about 6.7% compared to the 2024 fiscal year. The main reasons for the decrease in net profit after tax for this year include: a gain of approximately RMB 3.31 billion from the sale of equity interests in a wholly-owned subsidiary of the group in the previous year; an exchange loss of approximately RMB 2.56 billion due to the appreciation of the US dollar in 2025 (compared to an exchange gain of approximately RMB 1.055 billion in 2024).
Related Articles

MICROTECH MED-B(02235) invested 641,000 Hong Kong dollars on March 31 to repurchase 88,000 shares.

Shanghai Fosun Pharmaceutical (02196): FXB0871 approved for clinical trials in locally advanced or metastatic solid tumors.

CHINA PENGFEI (03348) released its annual performance with a net profit attributable to shareholders of 101 million yuan, an increase of 50.02% year-on-year.
MICROTECH MED-B(02235) invested 641,000 Hong Kong dollars on March 31 to repurchase 88,000 shares.

Shanghai Fosun Pharmaceutical (02196): FXB0871 approved for clinical trials in locally advanced or metastatic solid tumors.

CHINA PENGFEI (03348) released its annual performance with a net profit attributable to shareholders of 101 million yuan, an increase of 50.02% year-on-year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


